17,261 trials
Primary Open-angle Glaucoma and Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Week 2 — 18.19; 19.15 mmHg
Macular Degeneration
Primary: Percentage of Participants With Stable Vision — 97.6 percentage of participants
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs) — 60.2; 57.0 Percentage
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Objective Response According to RECIST 1.1 Criteria — 2; 27; 1 Participants
Crohn's Disease
Primary: Crohn's Disease Activity Index (CDAI) Response (Clinical Response or Remission) at Week 6 — 25.0; 43.3; 48.4 percentage of subjects
HIV Infection · Alcohol Use · Pain
Primary: Medication Tolerability Measured Via a 0-100 Visual Analog Scale — 90.7; NA score on a scale
Breast Cancer
Primary: Rate of Pathologic Complete Response (pCR) — 0; 0 Participants
Breast Cancer
Primary: Percentage of Patients Who Are Progression Free at 6 Months or Later. — 86 percentage of partcipants
Breast Cancer
Primary: Percent of Participants Experiencing Cardiac Events at 1 Year — 3.6 percentage of participants
Obesity
Primary: Stool Calories During OF and UF — 5.8; 8.9 percentage of calorie intake
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA) · Severe Aplastic Anemia (SAA)
Primary: Number of Participants Who Engrafted by Day 42 — 30 Participants
Immunologic Deficiency Syndromes
Primary: Survival — 12 Participants
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) — 0; 0 Participants
Clear Cell Renal Carcinoma
Primary: Phase 1b: Maximum Safe Dose of Treatment Regimen — 15 mg/kg
Pulmonary Embolism · Thrombotic Disease
Primary: Number of Participants Experiencing Adjudicated Clinically Relevant Bleeding Events Following Intravenous Infusion of DS-1040b or Placebo in Addition to Standard of Care…